Drug Profile
SHR 7390
Alternative Names: SHR7390Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Fudan University; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HER2 negative breast cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, In adults) in China (PO, Tablet)
- 01 Sep 2022 Jiangsu HengRui Medicine terminates a phase I trial for Solid tumours (Late-stage disease, Combination therapy) in China (PO) due to change in sponsor R&D strategy (NCT03182673)
- 04 Jun 2021 Efficacy and adverse events data from a (phase X trial in indication) presented at 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)